Inclusion Criteria

- INCLUSION CRITERIA:

2.1.1.1 Age greater than or equal to18 years.

2.1.1.2 ECOG performance status less than or equal to 2.

2.1.1.3 Life expectancy of greater than 3 months

2.1.1.4 Histologically confirmed cancer

2.1.1.5 Extracranial metastatic cancer or locally advanced cancer for which palliative
radiotherapeutic management would be appropriate (no more than two sites will be treated
on this trial)

2.1.1.6 Patients must have measurable or evaluable disease at the site(s) requiring
radiation

2.1.1.7 Adequate marrow and organ function defined as

- absolute neutrophil count (ANC) > 1.5 times 10(9)/L,

- platelet count > 100 times 10(9),

- hemoglobin > 9 g/L.

- creatinine clearance greater than or equal to 60 mL/min/1.73 m(2) for patients with
creatinine levels above institutional normal

- serum bilirubin < 1.5 times upper limit reference range (ULRR),

- alanine aminotransferase (ALT), aspartate aminotransferase (AST), or

alkaline phosphatase (ALP) < 2.5 times the ULRR (< 5 times the ULRR in the presence

of liver metastases)

2.1.1.8 Female patients of child bearing potential must either be surgically sterile to
prevent pregnancy, be at least 1-year post-menopausal, or have had no menses for 12
months, or agree to use reliable methods of contraception (oral contraceptives, barrier
methods, approved contraceptive implant, long-term injectable contraception, copper banded
intrauterine device, tubal ligation or abstinence) from time of screening until 4 weeks
after discontinuing study treatment. It is not known whether ECI301 has the capacity to
induce hepatic enzymes so hormonal contraceptives should be combined with a barrier method
of contraception.

2.1.1.9 Male patients must agree to use barrier contraception (i.e. condoms) and refrain
from donating sperm from the start of dosing until 16 weeks after discontinuing study
treatment. If male patients wish to father children they should be advised to arrange for
freezing of sperm prior to the start of study treatment.

EXCLUSION CRITERIA:

2.1.2.1 Pregnant or lactating females

2.1.2.2 Contraindications to radiotherapy (i.e. prior radiotherapy to the intended
treatment site)

2.1.2.3 Untreated or previously treated but progressive intracranial metastases (Patients
with previously treated intracranial metastases should have no clinical evidence of
progression and be at least 4 weeks from therapy for intracranial metastases)

2.1.2.4 Need for emergent radiotherapy (defined as need for radiotherapy within 24 hours
of consultation at the judgment of the treating radiation oncologist)

2.1.2.5 Active treatment with immunosuppressive therapy and subjects taking systemic
corticosteroid therapy for any reason including replacement therapy for hypoadrenalism

2.1.2.6 Chemotherapy, radiation therapy, Tamoxifen or investigational therapy during the 4
weeks prior to initiation of protocol therapy

2.1.2.7 History of rheumatoid arthritis, systemic lupus erythematosus, Sjogrens disease,
sarcoidosis, vasculitis, polymyositis, temporal arteritis or any other autoimmune disease

2.1.2.8 History of organ transplant

2.1.2.9 HIV, Hepatitis B, or Hepatitis C positivity

2.1.2.10 Uncontrolled intercurrent illness including, but not limited to, ongoing or
active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

2.1.2.11 Use of excluded immune modulating medications within 4 weeks prior to protocol
therapy, or requirement for concurrent use.